Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

NCT01772732 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Simotinib Hydrochloride

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.